CURAVEX Mark
CURAVEX CLINICAL MLOPS

Treatment Response Regression & Efficacy Governance

Patient Regimen Parameters

Input demographics and pharmacology to compute predicted improvement score.

Trial cohort: 18 – 79 years
Demographic strata
Permitted range: 50 – 850 mg
Course length: 5 – 60 days
Biostatistical Note

Prognosis reflects ensemble regression trained on canonical multi-cohort clinical trial response trajectories. Thresholds: Low (1.0–4.5), Medium (4.6–7.5), High (7.6–10.0).